Basel, Switzerland – 31 May 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 company, today announced its participation in the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 2-6 in Chicago, IL, and the BIO International Convention to be held June 5-8 in Boston, MA.

Alentis management will be present at the conferences. In case you want to schedule a meeting please reach out via info@alentis.ch.

About Alentis Therapeutics

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors with immune evasive properties and fibrotic diseases across multiple organs.

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US.